Home›Avutometinib Potassium And Defactinib Hydrochloride›Avutometinib Potassium And Defactinib Hydrochloride + Cyp3a Inducers

Does Avutometinib Potassium And Defactinib Hydrochloride Interact with Cyp3a Inducers?

Avutometinib Potassium And Defactinib Hydrochloride and Cyp3a Inducers have a major drug interaction according to U.S. FDA drug labeling data. Concomitant use decreases defactinib exposure, which may reduce the effectiveness of the drug combination. Avoid concomitant use. The mechanism involves defactinib is a cyp3a4 substrate; induction decreases exposure. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Major
Management
Close medical supervision required
Data Source
U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Avutometinib Potassium And Defactinib Hydrochloride and Cyp3a Inducers occurs because defactinib is a cyp3a4 substrate; induction decreases exposure. Clinically, this means concomitant use decreases defactinib exposure, which may reduce the effectiveness of the drug combination. avoid concomitant use. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.

What To Tell Your Doctor or Pharmacist

If you are taking Avutometinib Potassium And Defactinib Hydrochloride and your doctor is considering prescribing Cyp3a Inducers (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask how frequently you should be monitored while these are co-prescribed
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Avutometinib Potassium And Defactinib Hydrochloride(Avmapki Fakzynja Co-Pack)+💊 Cyp3a Inducers

Severity & Interaction Details

⚠️
major
Use with caution — major interaction
Serious risk of clinically significant harm. Generally avoid; if used, monitor closely.
Severity scale
MinorContra
On record
Yes
Drug A class
—
Drug B class
—
Source
NLP:avutometinib potassium and defactinib hydrochloride

What this means in plain English

Concomitant use decreases defactinib exposure, which may reduce the effectiveness of the drug combination. Avoid concomitant use.

What the FDA label says

"Defactinib is a CYP3A4 substrate; induction decreases exposure"

📖 Source: NLP:avutometinib potassium and defactinib hydrochloride

Share this result:XFacebookWhatsAppReddit
Add more drugs
Check Avutometinib Potassium And Defactinib Hydrochloride and Cyp3a Inducers against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.